welcome
ScienceDaily

ScienceDaily

Health

Health

Drug to slow Alzheimer's well tolerated outside of clinical trial setting

ScienceDaily
Summary
Nutrition label

81% Informative

Drug to slow Alzheimer's well tolerated outside of clinical trial setting.

Side effects of lecanemab are manageable, study finds.

Only 1% of patients experienced severe side effects that required hospitalization.

Lecanemab is an antibody therapy that clears amyloid plaque proteins, extending independent living by 10 months .

"This report may help patients and providers better understand the risks of treatment, which are lower in patients with very mild symptoms of Alzheimer's." Story Source: Journal Reference: - Madeline Paczynski et al. Lecanemab Treatment in a Specialty Memory Clinic . JAMA Neurology , 2025 DOI: : 10.1001 /jamaneurol.2025.1232 Cite This Page:.

VR Score

92

Informative language

98

Neutral language

61

Article tone

formal

Language

English

Language complexity

70

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

long-living

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links